LTZ Therapeutics, Inc.

The first half of July brought an explosion of venture capital fireworks with several $100m-plus financings for biopharmaceutical companies, but the pace of mega-round announcements has fizzled out in

Although financings of over $100m have become something of a rarity for Chinese biotechs, venture capital and private equity firms, as well as pharma companies, have recently made sizeable cash inject

The series C venture capital round that Tessera Therapeutics announced on 19 April – totaling more than $300m, the company said – shows that investors continue to be willing to invest large sums in